A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human β-globin gene transfer

Blood

Volumn 101, Issue 8, 2003, Pages 2932-2939

  Rivella, Stefano ^b   May, Chad ^b   Chadburn, Amy ^b   Rivière, Isabelle ^b   Sadelain, Michel ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ARTICLE; BETA THALASSEMIA; BIOAVAILABILITY; BLOOD CELL; BLOOD TRANSFUSION; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CHIMERA; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DNA VECTOR; ERYTHROPOIESIS; GENE TRANSFER; HEMATOPOIESIS; HUMAN; HUMAN CELL; LENTIVIRINAE; MATURATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; THALASSEMIA MAJOR; ANIMAL; BLOOD; C57BL MOUSE; CROSS BREEDING; CYTOLOGY; DISEASE MODEL; FEASIBILITY STUDY; FEMALE; GENE EXPRESSION PROFILING; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IRON OVERLOAD; LETHAL GENE; LIVER; MALE; MOUSE MUTANT; PRENATAL DEVELOPMENT; RADIATION CHIMERA;

GLOBIN; HYBRID PROTEIN;

ANIMALS; BETA-THALASSEMIA; CROSSES, GENETIC; DISEASE MODELS, ANIMAL; ERYTHROPOIESIS; FEASIBILITY STUDIES; FEMALE; GENE EXPRESSION PROFILING; GENE THERAPY; GENES, LETHAL; GENETIC VECTORS; GLOBINS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IRON OVERLOAD; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RADIATION CHIMERA; RECOMBINANT FUSION PROTEINS; TRANSDUCTION, GENETIC;

EID: 0037606048     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-10-3305     Document Type: Article

References (57)

1. Forget BG. Molecular mechanism of β thalassemia. Steinberg MH, Forget BG, Higgs DR, Nagel RL, eds. Disorders of Hemoglobin: Genetics, Pathophysiology and Clinical Management. Cambridge, United Kingdom: Cambridge University Press; 2001:252-276.
2. Weatherall DJ. Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Nat Rev Genet. 2001;2:245-255.
3. Orkin SH, Nathan DG. Hematology of Infancy and Childhood. Philadelphia, PA: WB Saunders Co; 1998:811-886.
4. Weatherall D. The Molecular Basis of Blood Diseases. Philadelphia, PA: WB Saunders Co; 2001:183-226.
5. Cooley TB, Lee P. A series of cases of splenomegaly in children with anemia and peculiar bone changes. Trans Am Pediatr Soc. 1925;37:29.
6. Tisdale J, Sadelain M. Toward gene therapy for disorders of hemoglobin synthesis. Semin Hematol. 2001;38:382-392.
7. Rivella S, Sadelain M. Genetic treatment of severe hemoglobinopathies: the combat against transgene variegation and transgene silencing. Semin Hematol. 1998;35:112-125.
8. Persons DA, Nienhuis AW. Gene therapy for the hemoglobin disorders: past, present, and future. Proc Natl Acad Sci U S A. 2000;97:5022-5024.
9. May C, Rivella S, Callegari J, et al. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human betaglobin. Nature. 2000;406:82-86.
10. May C, Rivella S, Chadburn A, Sadelain M. Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene. Blood. 2002;99:1902-1908.
11. Pawliuk R, Westerman KA, Fabry ME, et al. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science. 2001;294:2368-2371.
12. Skow LC, Burkhart BA, Johnson FM, et al. A mouse model for beta-thalassemia. Cell. 1983;34:1043-1052.
13. Shehee WR, Oliver P, Smithies O. Lethal thalassemia after insertional disruption of the mouse major adult beta-globin gene. Proc Natl Acad Sci U S A. 1993;90:3177-3181.
14. Yang B, Kirby S, Lewis J, Detloff PJ, Maeda N, Smithies O. A mouse model for beta 0-thalassemia. Proc Natl Acad Sci U S A. 1995;92:11608-11612.
15. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vectors achieve efficient gene delivery in vivo. Nat Biotechnol. 1997;15:871-875.
16. Porcu S, Kitamura M, Witkowska E, et al. The human beta globin locus introduced by YAC transfer exhibits a specific and reproducible pattern of developmental regulation in transgenic mice. Blood. 1997;90:4602-4609.
17. Franco RS, Lohmann J, Silberstein EB, et al. Time-dependent changes in the density and hemoglobin F content of biotin-labeled sickle cells. J Clin Invest. 1998;101:2730-2740.
18. Zhang D, Johnson MM, Miller CP, Pircher TJ, Geiger JN, Wojchowski DM. An optimized system for studies of EPO-dependent murine pro-erythroblast development. Exp Hematol. 2001;29:1278-1288.
19. Pace BS, Li Q, Stamatoyannopoulos G. In vivo search for butyrate responsive sequences using transgenic mice carrying A gamma gene promoter mutants. Blood. 1996;88:1079-1083.
20. Steinberg MH, Rodgers GP. Pharmacologic modulation of fetal hemoglobin. Medicine (Baltimore). 2001;80:328-344.
21. Rodgers GP, Saunthararajah Y. Advances in experimental treatment of beta-thalassaemia. Expert Opin Investig Drugs. 2001;10:925-934.
22. Ellis J, Pasceri P, Tan-Un KC, et al. Evaluation of beta-globin gene therapy constructs in single copy transgenic mice. Nucleic Acids Res. 1997;25:1296-1302.
23. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996;272:263-267.
24. Schroder A, Shinn P, Chen H, Berry C, Ecker J, Bushman F. HIV-1 integration in the human genome favors active genes and local hotspots. Cell. 2002;110:521-529.
25. Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science. 2002;295:868-872.
26. Pfeifer A, Ikawa M, Dayn Y, Verma IM. Transgenesis by lentiviral vectors: lack of gene silencing in mammalian embryonic stem cells and preimplantation embryos. Proc Natl Acad Sci U S A. 2002;99:2140-2145.
27. Molete JM, Petrykowska H, Bouhassira EE, Feng YQ, Miller W, Hardison RC. Sequences flanking hypersensitive sites of the beta-globin locus control region are required for synergistic enhancement. Mol Cell Biol. 2001;21:2969-2980.
28. Li Q, Harju S, Peterson KR. Locus control regions: coming of age at a decade plus. Trends Genet. 1999;15:403-408.
29. Higgs DR. Do LCRs open chromatin domains? Cell. 1998;95:299-302.
30. Grosveld F. Activation by locus control regions? Curr Opin Genet Dev. 1999;9:152-157.
31. Bulger M, Groudine M. Looping versus linking: toward a model for long-distance gene activation. Genes Dev. 1999;13:2465-2477.
32. Paszty C, Brion CM, Manci E, et al. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science. 1997;278:876-878.
33. Trudel M, Saadane N, Garel MC, et al. Towards a transgenic mouse model of sickle cell disease: hemoglobin SAD. EMBO J. 1991;10:3157-3165.
34. Case SS, Price MA, Jordan CT, et al. Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors. Proc Natl Acad Sci U S A. 1999;96:2988-2993.
35. Sutton RE, Reitsma MJ, Uchida N, Brown PO. Transduction of human progenitor hematopoietic stem cells by human immunodeficiency virus type 1-based vectors is cell cycle dependent. J Virol. 1999;73:3649-3660.
36. Guenechea G, Gan OI, Inamitsu T, et al. Transductioh of human CD34+ CD38- bone marrow and cord blood-derived SCID-repopulating cells with third-generation lentiviral vectors. Mol Ther. 2000;1:566-573.
37. Heim DA, Dunbar CE. Hematopoietic stem cell gene therapy: towards clinically significant gene transfer efficiency. Immunol Rev. 2000;178:29-38.
38. Sadelain M, Frassoni F, Riviere I. Issues in the manufacture and transplantation of genetically modified hematopoietic stem cells. Curr Opin Hematol. 2000;7:364-377.
39. Sirven A, Ravet E, Charneau P, et al. Enhanced transgene expression in cord blood CD34(+)-derived hematopoietic cells, including developing T cells and NOD/SCID mouse repopulating cells, following transduction with modified trip lentiviral vectors. Mol Ther. 2001;3:438-448.
40. Luther-Wyrsch A, Costello E, Thali M, et al. Stable transduction with lentiviral vectors and amplification of immature hematopoietic progenitors from cord blood of preterm human fetuses. Hum Gene Ther. 2001;12:377-389.
41. Donahue RE, Sorrentino BP, Hawley RG, An DS, Chen IS, Wersto RP. Fibronectin fragment CH-296 inhibits apoptosis and enhances ex vivo gene transfer by murine retrovirus and human lentivirus vectors independent of viral tropism in nonhuman primate CD34+ cells. Mol Ther. 2001;3:359-367.
42. Zielske SP, Gerson SL. Lentiviral transduction of P140K MGMT into human CD34(+) hematopoietic progenitors at low multiplicity of infection confers significant resistance to BG/BCNU and allows selection in vitro. Mol Ther. 2002;5:381-387.
43. Donahue RE, Dunbar CE. Update on the use of nonhuman primate models for preclinical testing of gene therapy approaches targeting hematopoietic cells. Hum Gene Ther. 2001;12:607-617.
44. An DS, Kung SK, Bonifacino A, et al. Lentivirus vector-mediated hematopoietic stem cell gene transfer of common gamma-chain cytokine receptor in rhesus macaques. J Virol. 2001;75:3547-3555.
45. Horn PA, Morris JC, Bukovsky AA, et al. Lentivirus-mediated gene transfer into hematopoietic repopulating cells in baboons. Gene Ther. 2002;9:1464-1471.
46. Rivella S, Sadelain M. Therapeutic globin gene delivery using lentiviral vectors. Curr Opin Mol Ther. 2002;4:505-514.
47. Cornetta K, Smith FO. Regulatory issues for clinical gene therapy trials. Hum Gene Ther. 2002;13:1143-1149.
48. Sadelain M, Riviere I. The advent of lentiviral vectors: prospects for cancer therapy. In: Gerson SL and Lattime EC, eds. Gene Therapy of Cancer. 2nd ed. New York, NY: Academic Press; 2002:109-124.
49. Salon P, Trono D. Lentiviral vectors for the gene therapy of lympho-hematological disorders. Curr Top Microbiol Immunol. 2002;261:211-227.
50. Stocking C, Bergholz U, Friel J, et al. Distinct classes of factor-independent mutants can be isolated after retroviral mutagenesis of a human myeloid stem cell line. Growth Factors. 1993;8:197-209.
51. Li Z, Dullmann J, Schiedlmeier B, et al. Murine leukemia induced by retroviral gene marking. Science. 2002;296:497.
52. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2003;348:255-256.
53. Sadelain M, Riviere I. Sturm und drang over suicidal lymphocytes. Mol Ther. 2002;5:655-657.
54. Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med. 2002;346:1185-1193.
55. Sadelain M. Globin gene transfer for the treatment of severe hemoglobinopathies: a paradigm for stem cell-based gene therapy. J Gene Med. 2002;4:113-121.
56. Rivella S, Callegari J, May C, Tan C, Sadelain M. The cHS4 insulator increases the probability of retroviral expression at random chromosomal integration sites. J Vir. 2000;74:4679-4687.
57. Emery DW, Yannaki E, Tubb J, Stamatoyannopoulos G. A chromatin insulator protects retrovirus vectors from chromosomal position effects. Proc Natl Acad Sci U S A. 2000;97:350-354.